<DOC>
	<DOCNO>NCT01605487</DOCNO>
	<brief_summary>Main objective study evaluate efficacy rupatadine 20 mg 40 mg dos development symptom cold contact urticaria . For purpose , Peltier element-based electronic provocation device ( TempTest® , emo system GmbH , Berlin , Germany ) use . This allow skin exposure 12 different temperature 4 42 °C simultaneously standardize reproducible way thus determination individual temperature and/or stimulation time threshold . In addition mediator related activate must cell histamine , PAF , PGD2 identify period application stimulus appearance symptom cold urticaria characterize qualitatively quantitatively .</brief_summary>
	<brief_title>Study Assess Efficacy , Safety Mechanism Rupatadine Cold Urticaria</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<mesh_term>Cyproheptadine</mesh_term>
	<criteria>Informed consent sign date Reliable method contraception woman childbearing potential well man study 3 month thereafter . A highly effective method birth control define result low failure rate ( i.e . le 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , IUDs , sexual abstinence vasectomise partner Outpatients CCU 6 week . Urticaria symptom must comprise wheal itch contact cool skin . Provocation perform application Temptest®3.0 allow reproducible standardized cold provocation test identification temperature stimulation time threshold . Age 18 18 year . No participation clinical trial 1 month participation study Subjects inmates psychiatric ward , prison , state institution . Existing plan placement institution rule accord § 40 passage 1 , number 4 AMG ( Arzneimittelgesetz ) . The presence permanent severe disease , especially affect immune system , except urticaria cold urticaria The presence permanent gastrointestinal condition may influence oral therapy ( chronic diarrhoea disease , congenital malformation surgical mutilation gastrointestinal tract ) History presence epilepsy , significant neurological disorder , cerebrovascular attack ischemia History presence myocardial infarction cardiac arrhythmia require drug therapy ECG alteration repolarisation ( QTc prolongation &gt; 450ms ) Blood pressure &gt; 180/100 mmHg and/or heart rate &gt; 100/min . Evidence significant hepatic renal disease ( GOT and/or GPT 3 time upper reference value , serum creatinine 1.5 time upper reference value ) History hypersensitivity allergic reaction rupatadine ingredient antihistamine compound . Presence active cancer require chemotherapy radiation therapy Presence lactose galactose intolerance glucosegalactose malabsorption Simultaneous chronic spontaneous physical urticaria could interfere CCU clinical assessment Intake antihistamine antileukotrienes within 7 day begin study Intake oral depot corticosteroid within 14 day prior screen visit Use systemic immunosupressants/immunomodulators like cyclosporine A , dapsone , methotrexate , mycophenolate , chloroquine , comparable drug within 28 day prior screen visit . Use ketoconazole , erythromycin potential inhibitor isoenzyme CYP3A4 cytochrome P450 . Currently abuse drug alcohol Unwilling unable comply protocol Pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>